[1] |
Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences[J]. N Engl J Med, 2004, 350(11):1118-1129.
|
[2] |
Bzowej NH. Hepatitis B therapy in pregnancy[J]. Curr Hepat Rep, 2010, 9(4):197-204.
|
[3] |
Yogeswaran K, Fung SK. Chronic hepatitis B in pregnancy: unique challenges and opportunities[J]. Korean J Hepatol, 2011, 17(1):1-8.
|
[4] |
Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B[J]. Lancet, 2003, 362(9401):2089-2094.
|
[5] |
Lee C, Gong Y, Brok J, et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis[J]. BMJ, 2006, 332 (7537): 328-336.
|
[6] |
Burk RD, Hwang LY, Ho GY, et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load[J]. J Infect Dis, 1994, 170(6):1418-1423.
|
[7] |
Singh AE, Plitt SS, Osiowy C, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants[J]. J Viral Hepat, 2011, 18(7): 468-473.
|
[8] |
Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus:an Australian experience[J]. Med J Aust, 2009, 190(9): 489-492.
|
[9] |
Zou H, Chen Y, Duan Z, et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers[J]. J Viral Hepat, 2012, 19(2):e18-e25.
|
[10] |
Thibault V, Pichoud C, Mullen C, et al. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections[J]. J Clin Microbiol, 2007, 45(12):3948-3953.
|
[11] |
丁世涛,汤影子. 不同方法检测血清HBV DNA水平比较[J]. 现代生物医学进展,2011, 10(19):3658-3659.
|
[12] |
Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B[J]. N Engl J Med, 2007, 357(25): 2576-2588.
|
[13] |
Zheng Q, Jang JJ, Chen J, et al. Serum HBV DNA level at week 24 as a proper predictor for the effect of 2-year lamivudine treatment[J]. Clin Med J (Engl), 2011, 124(8):1257-1260.
|
[14] |
Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response[J]. Hepatology, 2007, 46(6):1695-1703.
|
[15] |
杨柳絮,赵中夫. 拉米夫定治疗4周检测乙型肝炎病毒DNA水平预测104周疗效的价值[J]. 中国药物与临床,2011, 11(7):784-786.
|
[16] |
Degli Esposti S, Shah D. Hepatitis B in pregnancy: challenges and treatment[J]. Gastroenterol Clin North Am, 2011, 40(2):355-372.
|
[17] |
Mahtab MA, Rahman S, Khan M, et al. Etiology of fulminant hepatic failure: experience from a tertiary hospital in Bangladesh[J]. Hepatobiliary Pancreat Dis Int, 2008, 7(2):161-164.
|
[18] |
Tse KY, Ho LF, Lao T, el al. The impact of maternal HBsAg carrier status on pregnancy outcomes:a case-control study[J]. J Hepatol, 2005, 43(5):771-775.
|
[19] |
Wong S, Chan LY, Yu V, et al. Hepatitis B carrier and perinatal outcome in singleton pregnancy[J]. Am J Perinatol, 1999, 16(9):485-488.
|
[20] |
Safir A, Levy A, Sikuler E, et al. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome[J]. Liver Int, 2010, 30(5):765-770.
|